Lead Product(s): GEN-001,Avelumab
Therapeutic Area: Oncology
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.